The Senior Vice President Global Assets Lead Dysport Therapeutic & IPN10200 Tx is the single point of accountability for Ipsen’s therapeutic neuromodulator portfolio, integrating leadership of:
• Dysport Therapeutics (Tx) — a globally established brand in spasticity, cervical dystonia, and potentially chronic migraine.
• IPN10200 Therapeutics (Tx) — a next‑generation neurotoxin currently in Phase II.

This newly created role reflects Ipsen’s transition to a unified, enterprise‑level therapeutic leadership model. The VP sets the long‑term strategy, drives execution across development, evidence, access, operations, and commercialization, and ensures value maximisation across both assets while providing high‑visibility leadership to the Executive Leadership Team.

The role combines two distinct accountabilities under a single senior leader:

Dysport Therapeutic (Tx) — Global Asset Lead:
Accountable for the full strategic, clinical, medical, access, operational, and commercial trajectory of a global, commercialised asset with active lifecycle expansion, including the major planned indication expansion in migraine.

IPN10200 Therapeutic (Tx) — Global Asset Lead:
Accountable for building a differentiated, insight‑driven early global brand strategy and shaping the future value of an innovative Phase II molecule, ensuring the foundation for a best‑in‑class global launch as the asset advances to late‑stage development.

This is the first role within Ipsen’s Asset‑Centric Model to combine leadership of two therapeutic assets, reflecting the strategic importance and interdependency of Dysport and IPN10200.

Through unified and disciplined leadership, the VP ensures single‑point accountability for strategy, performance, and governance across both assets, connecting strategic direction, planning, and execution seamlessly across R&D, Medical, Commercial, Market Access, Tech Ops, and Regions/Affiliates.

Main Responsibilities & Technical Competencies

Strategic Leadership of the Therapeutic Neuroscience Portfolio
• Define and lead the unified therapeutic strategy for Ipsen’s neuromodulator portfolio, ensuring a coherent long‑term vision across Dysport and IPN10200.
• Own the Integrated Asset Strategy (IASP) for both assets, including TPP/TVP, CDP, IEGP, lifecycle management roadmap, country prioritization, and business case development.
• Drive enterprise‑level scenario planning to optimize indication sequencing, launch sequencing, competitive positioning, and long‑term value creation.

Dysport Therapeutics (Tx) — Global Asset Leadership
• Lead the end‑to‑end strategic, clinical, medical, access, operational, and commercial trajectory of Dysport, ensuring sustained performance in established indications and successful expansion into new ones such as migraine.
• Oversee lifecycle management, evidence generation, pricing and access strategy, and geographic expansion to support long‑term competitive differentiation.
• Ensure strong cross‑functional execution and alignment with regional and affiliate teams to maximize in‑market performance and patient impact.

IPN10200 Therapeutics (Tx) — Global Development & Early Brand Leadership
• Lead the development strategy for IPN10200 through Phase II and into pivotal development, ensuring scientific, regulatory, clinical, and commercial readiness.
• Shape early global brand positioning and differentiation, ensuring development, CMC, regulatory, and evidence strategies support future value claims and launch success.
• Integrate commercial, competitive, and patient insights early to influence critical decisions including clinical design, target label, launch sequencing, and access strategy.

Cross‑Functional Leadership & Operating Model Excellence
• Lead high‑performing cross‑functional Asset Teams, ensuring clarity of roles, disciplined execution, and adherence to ACM principles.
• Oversee functional Sub‑Teams (Clinical Development, Evidence Generation, Target Value Team, CMC/TechOps, Commercial/Brand, Safety, Regulatory) to deliver integrated planning and execution.
• Ensure robust risk management, scenario planning, KPI tracking, and cross‑functional decision‑making across both development and commercial phases.

Governance & Decision‑Making Excellence
• Lead preparation and presentation of governance packages for PSC, PC, PFR, and GBOC, ensuring decision‑ready materials and strategic clarity.
• Serve as the single point of accountability for escalating risks, resolving cross‑functional issues, and enabling timely enterprise decisions.
• Ensure consistency, quality, and accuracy of strategic updates, business cases, milestone deliverables, and scenario analyses.

External Leadership & Ecosystem Engagement
• Represent Ipsen to global scientific experts, investigators, payers, patient organizations, and industry partners, strengthening Ipsen’s leadership in neuromodulation.
• Shape the external scientific and therapeutic narrative for Dysport and IPN10200 to ensure credibility, differentiation, and alignment with the evolving competitive landscape.
• Provide insight and guidance on external innovation and business development opportunities relevant to the future neuroscience portfolio.

People & Culture Leadership
• Build, inspire, and develop high‑performing global teams in a matrix environment, fostering collaboration and cross‑functional accountability.
• Promote a culture grounded in enterprise mindset, patient centricity, and high‑quality decision‑making.
• Develop future leadership talent and ensure strong succession planning across development, medical, commercial, and operational functions.

Knowledge & Experience

Capabilities

• Strategic thinker able to connect scientific, medical, and commercial insights into coherent plans 
• Strong analytical, forecasting, and scenario‑modelling ability 
• Exceptional communication and influencing skills 
• Demonstrated ability to operate effectively in complex, matrixed global environments 
• High ethical standards and commitment to patient value

Knowledge & Experience (essential):

• 20+ years of progressive experience across strategy, commercial, and operational leadership roles years in pharma/biotech with extensive global leadership experience.

• Demonstrated leadership of large, globally scaled brands, ideally including responsibility for assets with >$1B annual revenue or with clear billion‑dollar growth potential. 

• Experience leading assets in high‑prevalence / mass‑market diseases. Experience in high‑prevalence, fast‑evolving or highly competitive therapeutic areas (e.g., migraine, immunology, diabetes) an advantage.

• Proven ability to shape global market environments (guidelines, treatment paradigms, payer positioning) for diseases with large patient populations and complex care pathways. 

• Track record influencing late‑stage development and leading global launches in competitive, dynamic, or fast‑evolving markets. 

• Proven record in leading global commercial brands with active lifecycle management

• Significant experience engaging global KOLs, major markets (US/EU5/China), and payers in disease areas requiring broad physician adoption and competitive differentiation.

• Global launch leadership across multiple major markets (US, EU5, China), including payer negotiations, diverse HTA landscapes, and complex cross‑regional coordination.

• Proven track record of delivering results across local (in-market), regional, and global settings, with a strong understanding of market dynamics and cross-functional alignment.

• Demonstrated ability to shape clinical development strategy (TPP/TVP alignment, endpoint strategy, comparator selection, regulatory interactions) informed by commercial, access, and patient insights.

• Deep expertise in strategic planning, organizational transformation, operational excellence, and business execution.

• Strong business and commercial acumen, with experience driving growth initiatives and leading cross-functional programs in matrix organizations.

Education / Certifications (essential):

• Advanced degree in Business, Economics, Life Sciences or related discipline.

• MBA or equivalent business qualification preferred

Education / Certifications (preferred):

•  Additional certifications in project management, transformation leadership, or change management are a plus

Language(s) (essential):

•  English (fluent – spoken and written)

Language(s) (preferred):

• Additional languages e.g., French or other a benefit